We show for the first time that inhibition of the angiopoietin/Tie2 axis in human tumor cells, using the preclinical version of Trebananib, induces immunogenic modulation and increases the susceptibility of tumor cells to antigen-specific lysis. This evidence concerns the gene TEK and neoplasm.